Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ziritaxestat · GLPG-1690, G-451990

Small molecule · developed by Lakefront Biotherapeutics NV

Phase 3 Most advanced trial (none active)
LKFT Developer
1 Registered trials

What is Ziritaxestat?

Ziritaxestat (GLPG1690) is an oral tablet studied in idiopathic pulmonary fibrosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
GLPG-1690, G-451990
Drug type
Small molecule
Therapy area
Respiratory
Developer
Lakefront Biotherapeutics NV (LKFT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
I02418V13W

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03733444 Phase 3 Idiopathic Pulmonary Fibrosis Terminated LKFT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic Pulmonary Fibrosis

More from Lakefront Biotherapeutics NV

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LKFT page.

Follow LKFT, the company behind Ziritaxestat

See LKFT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LKFT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.